NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted
This article was originally published in The Tan Sheet
Executive Summary
NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter
You may also be interested in...
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing
NVE Offers Ephedra Study Funds; Metabolife Backs Mandatory Health Reports
NVE Pharmaceuticals will provide funding for "NIH or another appropriate government body to independently study the long-term safety of ephedra," the Newton, N.J.-based firm's President Robert Occhifinto testified at a July 23 Capitol Hill hearing